TRUST trial: BAY 86‐6150 use in haemophilia with inhibitors and assessment for immunogenicity-Reference-Cited by-同舟云学术

TRUST trial: BAY 86‐6150 use in haemophilia with inhibitors and assessment for immunogenicity

Published:2016-08-08 Issue:6 Volume:22 Page:873-879
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Mahlangu J.¹,Paz P.²,Hardtke M.³,Aswad F.²,Schroeder J.³

Affiliation:

1. Haemophilia Comprehensive Care Centre Department of Molecular Medicine and Haematology Faculty of Health Sciences University of the Witwatersrand and National Health Laboratory Service Johannesburg South Africa

2. Global Biologics Research Lead Discovery Bayer San Francisco CA USA

3. Global Clinical Development Bayer Pharma AG Berlin Germany

Funder

Bayer

Biogen

CSL Behring

Novo Nordisk

Roche

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.12994

Reference26 articles.

1. Guidelines for the management of hemophilia

2. Inhibitors: our greatest challenge. Can we minimize the incidence?

3. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice

4. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical, Laboratory, and Molecular Aspects of Factor VII Deficiency;Seminars in Thrombosis and Hemostasis;2024-08-29

2. Site-directed mutagenesis of tissue factor pathway inhibitor–binding exosite D60A on factor VII results in a new factor VII variant with lower coagulant activity;Research and Practice in Thrombosis and Haemostasis;2024-01

3. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors;Expert Review of Hematology;2023-09-25

4. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

5. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors;Blood Advances;2022-06-08